WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005030776) PYRAZOLOPYRROLE DERIVATIVES AS PROTEIN KINASE INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/030776    International Application No.:    PCT/US2004/031610
Publication Date: 07.04.2005 International Filing Date: 23.09.2004
IPC:
A61K 31/41 (2006.01), A61K 45/06 (2006.01), C07D 487/04 (2006.01)
Applicants: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139 (US) (For All Designated States Except US).
BINCH, Hayley [GB/GB]; (GB) (For US Only).
EVERITT, Simon [GB/GB]; (GB) (For US Only).
MAZZEI, Francesca [GB/GB]; (GB) (For US Only).
ROBINSON, Daniel [GB/GB]; (GB) (For US Only)
Inventors: BINCH, Hayley; (GB).
EVERITT, Simon; (GB).
MAZZEI, Francesca; (GB).
ROBINSON, Daniel; (GB)
Agent: VERTEX PHARMACEUTICALS INCORPORATED; 130 Waverly Street, Cambridge, MA 02139 (US)
Priority Data:
60/505,236 23.09.2003 US
Title (EN) PYRAZOLOPYRROLE DERIVATIVES AS PROTEIN KINASE INHIBITORS
(FR) DERIVES DE PYRAZOLOPYRROLE UTILISES EN TANT QU'INHIBITEURS DE PROTEINES KINASES
Abstract: front page image
(EN)The present invention provides compounds of formula (I): or a pharmaceutically acceptable derivative thereof, wherein A, B, Q, R1, and R2 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT or PDK1 kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds, and methods of utilizing those compositions in the treatment of various disorders.
(FR)L'invention concerne des composés de formule (I) ou un de leurs dérivés pharmaceutiquement acceptables, A, B, Q, R1, et R2 étant spécifiés dans la description. Lesdits composés sont des inhibiteurs de la protéine kinase, en particulier des inhibiteurs de la kinase AKT ou PDK1, de protéines kinases de mammifères impliquées dans les troubles poliférants et neurodégénératifs. L'invention concerne également des compositions pharmaceutiques comprenant les composés de l'invention, des procédés pour préparer les composés, et des procédés d'utilisation desdites compositions dans le traitement de nombreux troubles.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)